Q2 2020 13F Holders as of 30 Jun 2020
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
6,235,531
-
Total 13F shares
-
8,121,087
-
Share change
-
+2,075,508
-
Total reported value
-
$430,587,215
-
Put/Call ratio
-
48%
-
Price per share
-
$53.01
-
Number of holders
-
103
-
Value change
-
+$116,997,084
-
Number of buys
-
73
-
Number of sells
-
29
Institutional Holders of BioXcel Therapeutics, Inc. - Common Stock, par value $0.001 per share (BTAI) as of Q2 2020
As of 30 Jun 2020,
BioXcel Therapeutics, Inc. - Common Stock, par value $0.001 per share (BTAI) was held by
103 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
8,121,087 shares.
The largest 10 holders included
STATE STREET CORP, BlackRock Inc., Artemis Investment Management LLP, VANGUARD GROUP INC, ALLIANCEBERNSTEIN L.P., Avidity Partners Management LP, ACUTA CAPITAL PARTNERS, LLC, CITADEL ADVISORS LLC, Logos Global Management LP, and MASSACHUSETTS FINANCIAL SERVICES CO /MA/.
This page lists
103
institutional shareholders reporting positions in this security
for the Q2 2020 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.